ArticleJournal for immunotherapy of cancer2022

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.

Laura T Morton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.